A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
HIV Infection
Interventions
DRUG

efavirenz

DRUG

tenofovir

DRUG

abacavir/lamivudine

Trial Locations (58)

10011

GSK Investigational Site, New York

10014

GSK Investigational Site, New York

11794

GSK Investigational Site, Stony Brook

12208

GSK Investigational Site, Albany

14215

GSK Investigational Site, Buffalo

17033

GSK Investigational Site, Hershey

19102

GSK Investigational Site, Philadelphia

19107

GSK Investigational Site, Philadelphia

19601

GSK Investigational Site, Reading

20009

GSK Investigational Site, Washington D.C.

20036

GSK Investigational Site, Washington D.C.

23666

GSK Investigational Site, Hampton

24501

GSK Investigational Site, Lynchburg

28209

GSK Investigational Site, Charlotte

30033

GSK Investigational Site, Decatur

30309

GSK Investigational Site, Atlanta

30339

GSK Investigational Site, Atlanta

32206

GSK Investigational Site, Jacksonville

32804

GSK Investigational Site, Orlando

32806

GSK Investigational Site, Orlando

32960

GSK Investigational Site, Vero Beach

33133

GSK Investigational Site, Miami

33136

GSK Investigational Site, Miami

33145

GSK Investigational Site, Fort Lauderdale

33161

GSK Investigational Site, North Miami

33308

GSK Investigational Site, Fort Lauderdale

33316

GSK Investigational Site, Fort Lauderdale

33602

GSK Investigational Site, Tampa

33901

GSK Investigational Site, Fort Myers

54301

GSK Investigational Site, Green Bay

55404

GSK Investigational Site, Minneapolis

60657

GSK Investigational Site, Chicago

67214

GSK Investigational Site, Wichita

70115

GSK Investigational Site, New Orleans

75208

GSK Investigational Site, Dallas

75246

GSK Investigational Site, Dallas

75708

GSK Investigational Site, Tyler

76104

GSK Investigational Site, Fort Worth

77030

GSK Investigational Site, Houston

80205

GSK Investigational Site, Denver

80220

GSK Investigational Site, Denver

80528

GSK Investigational Site, Fort Collins

85006

GSK Investigational Site, Phoenix

90033

GSK Investigational Site, Los Angeles

92708

GSK Investigational Site, Fountain Valley

97210

GSK Investigational Site, Portland

97219

GSK Investigational Site, Portland

98104

GSK Investigational Site, Seattle

98405

GSK Investigational Site, Tacoma

94115-1931

GSK Investigational Site, San Francisco

20007-2113

GSK Investigational Site, Washington D.C.

46202 - 5124

GSK Investigational Site, Indianapolis

70127-0800

GSK Investigational Site, New Orleans

08844

GSK Investigational Site, Hillsborough

87131-0001

GSK Investigational Site, Albuquerque

45267-0405

GSK Investigational Site, Cincinnati

02903

GSK Investigational Site, Providence

29206-4713

GSK Investigational Site, Columbia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00053638 - A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy | Biotech Hunter | Biotech Hunter